SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

European CMO market will double in just 6 years, says Frost & Sullivan

By Natalie Morrison , 15-Mar-2012
Last updated on 24-Apr-2012 at 14:31 GMT

European CMO market will double in just 6 years, says Frost & Sullivan
European CMO market will double in just 6 years, says Frost & Sullivan
Loading...

The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost & Sullivan’s Aiswariya Chidambaram.

In a report titled ‘European Pharmaceutical and Biotech Contract Manufacturing Markets’ the healthcare market analyst said biosimilars is a key driving factor behind the expected growth.

Speaking to Outsourcing-Pharma, she said: “When biotech drugs come out of patent they cannot be easily re-produced like how pharmaceutical drugs can be, because it is difficult to establish the reproducibility when it comes to biotech drugs due to the complex manufacturing process, the investment and technology resources required.

“What a company tends to do is once a drug comes out of patent, even generic drugs, they leverage the support of CMOs (contract manufacturing organisations) who have all this in place.”

She added that with the expected growth, many European CMOs are on the verge of expansion. However Chidambaram warned that those looking to grow should make “cautious decisions”.

 “It’s tricky,” she said. “It’s where anticipating capacity demand comes into play. There are a lot of factors that could affect demand for certain markets, for instance the product requirements the approvals rates by regulatory bodies or the new technologies.

“It Is essential companies take this into account before investing so that they are not hit by over-capacity in the long run.”

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Sue Mackay

Research nursing team manager, ResearchNurses.co

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell

Key Industry Events

 

Access all events listing

Our events, Events from partners...